Active Pharmaceutical Ingredients
In 2020, Anvisa published a new framework for Active Pharmaceutical ingredients (APIs). Since then, Anvisa has issued the Letter of Suitability of the Active Pharmaceutical Ingredient (CADIFA) for APIs used in the manufacture of new, innovator, generic and similar drug products, in accordance with RDC 359/2020.
Supporting Materials
Normative
- RDC 359/2020 - This Resolution institutes the Active Pharmaceutial Ingredient Dossier (DIFA) and the Letter of Suitability of the Active Pharmaceutical Ingredient (CADIFA)
- IN 289/2024 - Establishes the optimized analysis procedure where assessments conducted by Equivalent Foreign Regulatory Authority (AREE) are used for analysis the letter of suitability of the active pharmaceutical ingredient (CADIFA)
Guidance
Related news
Cadifa Manual for Administrative Procedures: check out the new version
Anvisa publishes an updated version with guidelines .
Anvisa’s systems and the Internet Explorer: check the changes
Since Microsoft decided to discontinue the Internet Explorer, Anvisa recommends the use of the Internet Explorer Mode in Microsoft Edge.
Anvisa published normative instruction (IN 289/2024) and guidelines on Regulatory Reliance
Rules optimize the approval of drug products, biological products, and vaccines.